Pacer Advisors Inc. Has $13.90 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Key Points

• Pacer Advisors Inc. decreased its stake in Amphastar Pharmaceuticals by 64.5%, selling 870,978 shares and now holding approximately 1.01% of the company worth $13.9 million.
• Wall Street analysts have set lower price targets for Amphastar, with Wells Fargo reducing its target from $40 to $35 and JPMorgan from $45 to $30, both maintaining a cautious outlook on the stock.
• Amphastar Pharmaceuticals shares are currently trading at $22.37, down 0.6%, with a market capitalization of $1.05 billion and a 52-week range between $20.43 and $53.96.

Pacer Advisors Inc. lessened its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 64.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 479,390 shares of the company's stock after selling 870,978 shares during the period. Pacer Advisors Inc. owned about 1.01% of Amphastar Pharmaceuticals worth $13,898,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of AMPH. Signaturefd LLC increased its position in Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after acquiring an additional 520 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter worth $38,000. Tower Research Capital LLC TRC boosted its position in shares of Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the period. IFP Advisors Inc acquired a new stake in shares of Amphastar Pharmaceuticals in the first quarter worth $34,000. Finally, GAMMA Investing LLC boosted its position in Amphastar Pharmaceuticals by 46.6% during the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock valued at $39,000 after purchasing an additional 424 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Down 0.6%

NASDAQ:AMPH traded down $0.14 during trading hours on Friday, hitting $22.37. 329,130 shares of the stock were exchanged, compared to its average volume of 447,889. The company's 50 day moving average is $24.01 and its two-hundred day moving average is $27.24. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.43 and a twelve month high of $53.96. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $1.05 billion, a P/E ratio of 8.11 and a beta of 0.72.

Analysts Set New Price Targets

Several equities analysts have weighed in on AMPH shares. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.